An interventional study of Abciximab local infusion and No local infusion in Acute Anterior Myocardial Infarction, sponsored by Atrium Medical Corporation. Completed at 38 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-08.
Sponsored by Atrium Medical Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the following arms:
In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.
The primary objective of the study is to demonstrate that among subjects undergoing primary PCI for anterior STEMI treated with a bivalirudin monotherapy anticoagulation strategy, the intracoronary infusion of an abciximab bolus with or without thrombus aspiration prior to stent implantation, compared to no infusion with or without thrombus aspiration (standard of care), results in 1) reduced infarct size measured by cardiac MRI at 30 days (range -7 days/+14 days; i.e., between 23 and 44 days), 2) reduce microvascular obstruction (MVO) by cardiac MRI at 5 + 2 days (i.e., between 3 and 7 days), 3) enhanced ST-segment resolution, 4) improved myocardial perfusion, 5) reduced thrombus burden and angiographic complications, and 6) no increase in major and minor bleeding.
36 studies on the registry are indexed under Anterior Wall Myocardial Infarction; 5 are open to participants now.
This study's enrollment of 452 is above the median of 110 across 28 interventional studies indexed under Anterior Wall Myocardial Infarction.
Browse Anterior Wall Myocardial Infarction studies →Atrium Medical Corporation is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
Drug: Abciximab local infusion · Procedure: Thrombus aspiration
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
Drug: Abciximab local infusion
No local infusion of abciximab, thrombus aspiration.
Other: No local infusion · Procedure: Thrombus aspiration
No local infusion abciximab and no thrombus aspiration
Other: No local infusion
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
Intervention without local infusion
Thrombus aspiration
Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion
The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.
Time frame: 30 Days Post Index Procedure
Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration
The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.
Time frame: 30 Days
Between 28-Nov-09 and 02-Dec-11, 452 subjects meeting all clinical eligibility criteria were consented and enrolled at 37 US and European sites.
| Milestone | Local Infusion, Thrombus Aspiration | Local Infusion, no Aspiration | No Local Infusion, Thrombus Aspiration | No Local Infusion, no Aspiration |
|---|---|---|---|---|
| Started | 118 | 111 | 111 | 112 |
| Completed | 109 | 99 | 102 | 93 |
| Not completed | 9 | 12 | 9 | 19 |
The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.
| Percentage of Left Ventricular Mass | Abciximab Infusion | No Infusion | Combined |
|---|---|---|---|
| Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion | 15.1 (6.8 to 22.7) | 17.9 (10.3 to 25.4) | 17.2 (7.4 to 23.6) |
The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.
| Percentage of Total Myocardial Mass | Thrombus Aspiration | No Aspiration | Combined |
|---|---|---|---|
| Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration | 17.0 (9.0 to 22.8) | 17.3 (7.1 to 25.5) | 17.2 (7.4 to 23.6) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Local Infusion, Thrombus Aspiration | — | 31/118 (26.3%) | — |
| Local Infusion, No Aspiration | — | 31/111 (27.9%) | — |
| No Local Infusion, Thrombus Aspiration | — | 35/111 (31.5%) | — |
| No Local Infusion, No Aspiration | — | 41/112 (36.6%) | — |
| Event | Local Infusion, Thrombus Aspiration | Local Infusion, No Aspiration | No Local Infusion, Thrombus Aspiration | No Local Infusion, No Aspiration |
|---|---|---|---|---|
| Heart failureCardiac disorders | 2/118 | 4/111 | 4/111 | 11/112 |
| Angina pectorisCardiac disorders | 7/118 | 7/111 | 6/111 | 5/112 |
| Cardiac deathGeneral disorders | 5/118 | 2/111 | 2/111 | 2/112 |
| Congestive heart failureCardiac disorders | 1/118 | 3/111 | 1/111 | 0/112 |
| Intracardiac thrombusCardiac disorders | 2/118 | 3/111 | 3/111 | 0/112 |
| Cardiogenic shockCardiac disorders | 1/118 | 1/111 | 0/111 | 3/112 |
| GI bleedGastrointestinal disorders | 1/118 | 0/111 | 1/111 | 3/112 |
| Myocardial infarctionCardiac disorders | 0/118 | 1/111 | 2/111 | 1/112 |
| Chest painGeneral disorders | 2/118 | 1/111 | 2/111 | 2/112 |
| Chest pain (non-cardiac)General disorders | 0/118 | 0/111 | 2/111 | 0/112 |
| Age, Categorical(Participants) | Local Infusion, Thrombus Aspiration | Local Infusion, no Aspiration | No Local Infusion, Thrombus Aspiration | No Local Infusion, no Aspiration | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 80 | 79 | 61 | 67 | 287 |
| >=65 years | 38 | 32 | 50 | 45 | 165 |
| Age Continuous(years) | Local Infusion, Thrombus Aspiration | Local Infusion, no Aspiration | No Local Infusion, Thrombus Aspiration | No Local Infusion, no Aspiration | Total |
|---|---|---|---|---|---|
| Median | 60.0 (52.0 to 66.0) | 56.0 (49.0 to 68.0) | 62.0 (53.0 to 73.0) | 62.5 (52.5 to 71.0) | 61.0 (52.0 to 72.0) |
| Sex: Female, Male(Participants) | Local Infusion, Thrombus Aspiration | Local Infusion, no Aspiration | No Local Infusion, Thrombus Aspiration | No Local Infusion, no Aspiration | Total |
|---|---|---|---|---|---|
| Female | 34 | 27 | 26 | 31 | 118 |
| Male | 84 | 84 | 85 | 81 | 334 |
| Region of Enrollment(participants) | Local Infusion, Thrombus Aspiration | Local Infusion, no Aspiration | No Local Infusion, Thrombus Aspiration | No Local Infusion, no Aspiration | Total |
|---|---|---|---|---|---|
| United States | 14 | 15 | 12 | 12 | 53 |
| Poland | 25 | 24 | 27 | 23 | 99 |
| Austria | 13 | 14 | 11 | 9 | 47 |
| Netherlands | 14 | 11 | 10 | 15 | 50 |
| Germany | 22 | 21 | 19 | 19 | 81 |
| United Kingdom | 30 | 26 | 32 | 34 | 122 |
The record gives a start of Sep 2009, a primary completion of Feb 2012 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anterior Wall Myocardial Infarction →
Atrium Medical Corporation